跳至主要内容
临床试验/NCT00143286
NCT00143286已完成3 期

A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline ( CP-526,555) for the Maintenance of Smoking Cessation

Pfizer23 个研究点 分布在 7 个国家目标入组 2,000 人开始时间: 2003年4月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Pfizer
入组人数
2,000
试验地点
23
主要终点
Continuous abstinence Weeks 13 -24.

研究概览

简要总结

The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.

排除标准

  • Subjects with clinically significant cardiovascular disease in the past 6 months.

结局指标

主要结局

Continuous abstinence Weeks 13 -24.

次要结局

  • Continuous abstinence Weeks 13-52
  • Long term quit rate at Week 52
  • 7-day Point Prevalence of abstinence at Weeks 24, 52
  • 4-week Point Prevalence of abstinence at Week 52
  • Time to first cigarette post randomization

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (23)

Loading locations...

相似试验

A 52-Week Multicenter Study Evaluating the Safety... | 临床试验